| Name | Title | Contact Details |
|---|---|---|
Sylvain Roy |
Chief Technology Officer | Profile |
Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.
CG Therapeutics Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children. Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen`s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers. Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.
Nines is a dynamic team applying world-class ML and AI expertise to the field of medicine.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.